The science behind the ArteraAI Prostate Test
Artera’s multimodal artificial intelligence (MMAI) biomarker test leverages a unique algorithm that assesses both the digital images from a patient’s biopsy and their clinical data. The AI combines this information to estimate long-term outcomes and predict whether a patient will benefit from hormone therapy.
Results can be shared within 2-3 days after receipt of the patient’s specimen. The algorithm was developed using large datasets, from thousands of patients and tens of thousands of pathology slide images, and has been clinically validated using multiple Phase 3 randomized trials.
Suitable for patients across all risk groups
The ArteraAI Prostate Test can be used for patients across all NCCN risk groups, with 10-year risk of distant metastasis (DM) and prostate cancer specific mortality (PCSM) reported and can be used to assess how aggressive the cancer is.
For lower-risk patientsFor patients with NCCN very low-, low-, or favorable intermediate-risk disease., the ArteraAI Prostate Test will also report the relative risk of adverse pathology (AP) at radical prostatectomy (RP) to help inform if active surveillance is a suitable management option.
For intermediate-risk patients, the ArteraAI Prostate Test can be used to predict if there will be a therapeutic benefit from adding ST-ADT to radiation therapy.
Predicting therapeutic benefit from hormone therapy
It is the first AI-enabled test to be included in the NCCN Guidelines® for Prostate Cancer, and the only test recommended for its predictive performance regarding the use of short-term ADT.Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.4.2024. ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed June 4, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Spratt DE, et al. NEJM Evidence. 2023;2(8):EVIDoa2300023. NCCN, National Comprehensive Cancer Network.
Current method
Men with intermediate localized prostate cancer are often treated with short-term androgen-deprivation therapy in combination with radiation therapy (RT + ST-ADT), but only ~⅓ of men actually benefit from it. This needlessly exposes them to the side effects of medical castration such as sexual dysfunction, cognitive impairment, and metabolic impairment.
Overall Analysis Population (RTOG 9408)
Shows marginal benefit to including short-term hormone therapy in combination with radiation therapy.
Hazard ratio: 0.64 (95% CI, 0.45-0.90, P = 0.01)
n = 1719 patients studied
With ArteraAI Prostate Test
The AI identifies the 1/3 of patients who may greatly benefit from short-term hormone therapy.Source: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300023
AI Biomarker Negative
Identify patients who are less likely to benefit from short-term hormone therapy.
Hazard ratio: 0.92 (95% CI, 0.59-1.43, P = 0.71)
n = 1046 patients studied
AI Biomarker Positive
Identify patients who may greatly benefit from short-term
hormone therapy.
Hazard ratio: 0.34 (95% CI, 0.19-0.63, P < 0.001)
n = 673 patients studied
Insights for all patient cohorts
ArteraAI Prostate Test is the first test that can predict therapy benefit, help inform active surveillance decision-making, and prognosticate long-term outcomes in localized prostate cancer.
Robust model validation
Multiple Phase 3 randomized trials with up to 15-year follow-up were used to develop and validate prognostic and predictive AI models. The prognostic model has also been validated across patients regardless of subsequent management options.Validation cohorts included patients who were managed with active surveillance, were treated with radiation therapy, or had a radical prostatectomy.
Representing diverse populations
African American men are disproportionately affected, making up 16.3% of prostate cancer patients. Artera’s models were developed using clinical trial data comprising approximately 20% African American men.Roach et al. 2022. Prostate cancer risk in African American men evaluated via digital histopathology multi-modal deep learning models developed on NRG Oncology phase III clinical trials. Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 108-108.
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.108
Ordering is easy with ArteraAI
The ArteraAI Prostate Test is a laboratory-developed testTesting is performed by ArteraAI, located at 6800 Southpoint Pkwy Suite 950, Jacksonville, Florida 32216. The ArteraAI Prostate Test was developed and its performance characteristics were determined by ArteraAI. This Laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA ‘88) as qualified to perform high-complexity clinical laboratory testing. This test is used for clinical purposes and should not be regarded as investigational or for research. This test has not been cleared or approved by the U.S. Food and Drug Administration. that is now clinically available through a single CLIA-certified laboratory in Jacksonville, FL.
-
The ArteraAI Prostate Test is intended to help clinicians determine the therapeutic benefit for patients who have been diagnosed with localized prostate cancer who have not yet received androgen deprivation therapy.
-
Yes! You can visit the ArteraAI Test Report page to explore each section of the report to better understand the results.
-
Currently, Artera cannot accept orders from New York. Artera is actively pursuing New York licensing and will provide future updates to its certification status.
-
After you reach out to us, a member of our Customer Success team will set up an account in the ArteraAI Portal to enable order submission.
-
No. Ordering of the ArteraAI Prostate Test is limited to clinicians whose license and scope of practice allows them to order the test. However, we encourage patients to share information about ArteraAI with their doctor.
-
Using the ArteraAI Prostate Test, results can be shared within 2-3 days after receipt of the patient’s specimen.
-
The out-of-pocket cost for the ArteraAI Prostate Test will be based on the patient’s insurance plan. If the patient is covered by Medicare Plan B, they should have zero out-of-pocket costs for the ArteraAI Prostate Test. If the patient is covered by private insurance, financial liability will be subject to the terms of their plan taking into consideration copays, coinsurance and deductibles. Patients should contact billing@artera.ai for additional questions about their estimated out-of-pocket liability for the test.
ArteraAI Prostate Test Guide 2024
This test is for patients who have been diagnosed with localized prostate cancer who have not yet received radiation therapy.
Artificial Intelligence in Prostate Cancer: Predicting Who ADT Can Benefit
Artera has developed multimodal AI (MMAI)-enabled predictive and prognostic biomarkers for patients with prostate cancer using large datasets from thousands of patients enrolled in Phase 3 randomized clinical trials.
Order the ArteraAI
Prostate Test for
your patient.
Start your order
